1. Home
  2. PFBC vs ERAS Comparison

PFBC vs ERAS Comparison

Compare PFBC & ERAS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Preferred Bank

PFBC

Preferred Bank

HOLD

Current Price

$87.34

Market Cap

1.2B

Sector

Finance

ML Signal

HOLD

Logo Erasca Inc.

ERAS

Erasca Inc.

HOLD

Current Price

$10.58

Market Cap

1.0B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
PFBC
ERAS
Founded
1991
2018
Country
United States
United States
Employees
N/A
N/A
Industry
Major Banks
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.2B
1.0B
IPO Year
1998
2021

Fundamental Metrics

Financial Performance
Metric
PFBC
ERAS
Price
$87.34
$10.58
Analyst Decision
Hold
Strong Buy
Analyst Count
3
9
Target Price
$102.67
$5.78
AVG Volume (30 Days)
106.8K
9.8M
Earning Date
01-22-2026
03-19-2026
Dividend Yield
3.73%
N/A
EPS Growth
7.99
N/A
EPS
10.41
N/A
Revenue
$281,236,000.00
N/A
Revenue This Year
$5.05
N/A
Revenue Next Year
$9.42
N/A
P/E Ratio
$8.24
N/A
Revenue Growth
5.27
N/A
52 Week Low
$71.90
$1.01
52 Week High
$103.05
$10.71

Technical Indicators

Market Signals
Indicator
PFBC
ERAS
Relative Strength Index (RSI) 40.73 79.74
Support Level $82.64 $9.05
Resistance Level $85.35 $10.71
Average True Range (ATR) 3.60 0.91
MACD -0.89 0.04
Stochastic Oscillator 32.19 92.24

Price Performance

Historical Comparison
PFBC
ERAS

About PFBC Preferred Bank

Preferred Bank is a commercial bank located in California. Its products and services are divided into Personal Banking, Business Banking, and Commercial Banking which includes Checking accounts, Savings accounts, CDs, Loans and Credit, Electronic banking, and Treasury Management. It provides personalized deposit services, real estate finance, commercial loans, and trade finance credit facilities to small and mid-sized businesses and their owners, entrepreneurs, real estate developers and investors, professionals, and high-net-worth individuals. The bank generates a majority of its revenue from Southern and Northern California and Flushing.

About ERAS Erasca Inc.

Erasca Inc is a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The company's product pipeline includes; Naporafenib, a pan-RAF inhibitor with first-in-class potential in NRASm melanoma, RAS Q61X tissue agnostic solid tumors, and other RAS/MAPK pathway-driven tumors, and ERAS-007 (oral ERK1/2 inhibitor) and ERAS-601 (oral SHP2 inhibitor), which target downstream and upstream nodes, respectively, of the RAS/MAPK pathway.

Share on Social Networks: